Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel brain-penetrant therapies for neuropsychiatric, neurodegenerative, and metabolic disorders. Its lead program, navacaprant, is a once-daily oral KOR antagonist in Phase 3 for major depressive disorder. The pipeline also includes NMRA-511 (V1aR antagonist for AD agitation), NMRA-898 (M4 PAM for schizophrenia), NMRA-215 (NLRP3 inhibitor for obesity), NMRA-GCase (Parkinson's disease), and NMRA-CK1 (ALS).
expected 2026-11-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-130388 | EDGAR | 94K words |
| 2025-03-03 | 2024-12-31 | 0000950170-25-030401 | EDGAR | 99K words |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027927 | EDGAR | 104K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001193125-26-350370 | EDGAR | 68K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269446 | EDGAR | 71K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104138 | EDGAR | 70K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069311 | EDGAR | 66K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125437 | EDGAR | 71K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091737 | EDGAR | 71K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054448 | EDGAR | 68K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057424 | EDGAR | 29K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-14 | 0001193125-26-350349 | EDGAR | 2K words |
| 2026-07-27 | 0001193125-26-316819 | EDGAR | 1K words |
| 2026-03-30 | 0001193125-26-130372 | EDGAR | 3K words |
| 2026-02-11 | 0001193125-26-045526 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009727 | EDGAR | 5K words |
| 2026-01-05 | 0001193125-26-001472 | EDGAR | 2K words |
| 2025-11-21 | 0001193125-25-291352 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-268046 | EDGAR | 2K words |
| 2025-10-27 | 0001193125-25-250677 | EDGAR | 1K words |
| 2025-10-27 | 0001193125-25-250656 | EDGAR | 1K words |
45 total filings indexed. 24 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001885522 |
| Ticker | NMRA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.neumoratx.com |
| Listed | 2023-09-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NMRA (~200 tokens, structured JSON with cryptographic provenance)